|View printer-friendly version|
|StemCyte and Fulgent Genetics Partner to Provide Comprehensive Genetic Analysis for Families|
BALDWIN PARK, Calif., Oct. 9, 2018 /PRNewswire/ -- StemCyte, a global regenerative therapeutics company, and Fulgent Genetics (NASDAQ: FLGT), a leading genetic testing company, are proud to announce a new partnership to offer comprehensive genetic testing to support the health of growing families. Two genetic tests, "Beacon Expanded Carrier Screening" and "Newborn Genetic Analysis (NGA)," will now be offered through StemCyte and powered by Fulgent Genetics.
Beacon Expanded Carrier Screening can help identify potential reproductive risks for current or future pregnancies. A carrier does not have signs or symptoms of a genetic disorder, but does carry a risk of having a child affected with a disorder. Awareness of an individual's carrier status can help them make more informed decisions for themselves and their families.
While Beacon Expanded Carrier Screening is intended to identify genetic risks present in parents, Newborn Genetic Analysis (NGA) is a unique test performed for newborns. NGA identifies DNA changes that could cause severe or life-altering symptoms in an infant. This analysis includes 255 genes and assesses over 200 disorders, covering many conditions beyond state legislated standards for newborn screening. NGA tests for early-onset conditions where early detection, intervention, and management could prove essential for the infant's overall health and quality of life.
Of the partnership, CEO of StemCyte Dr. Jonas Wang says, "We welcome our pregnant parents to enjoy the unique benefit [of genetic screening] for their family planning and reproductive health for a lifetime."
Ming Hsieh, Chairman and CEO of Fulgent Genetics, says, "We are excited to leverage the technology from our Beacon Carrier Screening and NGA tests to partner with StemCyte on their comprehensive family screening offering. We look forward to helping families make more informed health decisions now and in the future."
About Fulgent Genetics